Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/28/19
End: 05/31/20
Due: 05/31/21
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 08/31/17
Due: 08/31/18
Phase: N/A
Priority: Normal
Start: 09/01/21
End: 09/21/22
Due: 09/21/23
Phase: N/A
Priority: Normal
Start: 02/28/19
End: 04/30/20
Due: 04/30/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma | NCT03835871 | Adamis Pharmaceuticals Corporation | user2@example.com | None | 2019-02-28 | 2020-05-31 | 2021-05-31 | - | - | 2025-07-14 |
| Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | NCT01436214 | Adamis Pharmaceuticals Corporation | user2@example.com | None | 2011-08-31 | 2017-08-31 | 2018-08-31 | - | - | 2025-07-14 |
| Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. | NCT04729595 | Adamis Pharmaceuticals Corporation | user2@example.com | None | 2021-09-01 | 2022-09-21 | 2023-09-21 | - | - | 2025-07-14 |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma | NCT03834012 | Adamis Pharmaceuticals Corporation | user2@example.com | None | 2019-02-28 | 2020-04-30 | 2021-04-30 | - | - | 2025-07-14 |